[go: up one dir, main page]

WO2013081571A3 - Isolated lyssavirus nucleic acid and protein sequences - Google Patents

Isolated lyssavirus nucleic acid and protein sequences Download PDF

Info

Publication number
WO2013081571A3
WO2013081571A3 PCT/US2011/021309 US2011021309W WO2013081571A3 WO 2013081571 A3 WO2013081571 A3 WO 2013081571A3 US 2011021309 W US2011021309 W US 2011021309W WO 2013081571 A3 WO2013081571 A3 WO 2013081571A3
Authority
WO
WIPO (PCT)
Prior art keywords
isolated
lyssavirus
nucleic acid
protein sequences
lyssavirus nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/021309
Other languages
French (fr)
Other versions
WO2013081571A2 (en
Inventor
Ivan KUZMIN
Wanda MARKOTTER
Charles Rupprecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centers of Disease Control and Prevention CDC
US Department of Health and Human Services
Original Assignee
Centers of Disease Control and Prevention CDC
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centers of Disease Control and Prevention CDC, US Department of Health and Human Services filed Critical Centers of Disease Control and Prevention CDC
Anticipated expiration legal-status Critical
Publication of WO2013081571A2 publication Critical patent/WO2013081571A2/en
Publication of WO2013081571A3 publication Critical patent/WO2013081571A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

A new species of lyssavirus is presented including the whole genome sequence and the sequences of each of the structural genes. The Shimoni bat virus of the preset invention and structural proteins are used as vaccines or therapeutics for the prevention of amelioration of lyssavirus disease.
PCT/US2011/021309 2010-01-14 2011-01-14 Isolated lyssavirus nucleic acid and protein sequences Ceased WO2013081571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498810P 2010-01-14 2010-01-14
US61/294,988 2010-01-14

Publications (2)

Publication Number Publication Date
WO2013081571A2 WO2013081571A2 (en) 2013-06-06
WO2013081571A3 true WO2013081571A3 (en) 2013-10-17

Family

ID=48536218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021309 Ceased WO2013081571A2 (en) 2010-01-14 2011-01-14 Isolated lyssavirus nucleic acid and protein sequences

Country Status (1)

Country Link
WO (1) WO2013081571A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113480630B (en) * 2021-08-17 2022-06-21 贵州师范大学 Hepialus longissimus source antibacterial peptide MS-CATH and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263802A1 (en) * 2003-09-04 2006-11-23 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
WO2007047459A1 (en) * 2005-10-14 2007-04-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
US7238672B1 (en) * 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238672B1 (en) * 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
US20060263802A1 (en) * 2003-09-04 2006-11-23 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
WO2007047459A1 (en) * 2005-10-14 2007-04-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOTVINKIN, ALEXANDER D. ET AL.: "Novel lyssaviruses isolated from bats in Russia", EMERGING INFECTIOUS DISEASES, vol. 9, no. 12, 31 December 2003 (2003-12-31), pages 1623 - 1625 *
KUZMIN, IVAN V. ET AL.: "Possible emergence of West Caucasian bat virus in Africa", EMERGING INFECTIOUS DISEASES, vol. 14, no. 12, 31 December 2008 (2008-12-31), pages 1887 - 1889 *
KUZMIN, IVAN V. ET AL.: "Shimoni bat virus, a new representative of the Lyssavirus genus", VIRUS RESEARCH, vol. 149, no. 2, 6 February 2010 (2010-02-06), pages 197 - 210 *

Also Published As

Publication number Publication date
WO2013081571A2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
EA201391109A1 (en) NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE INCLUDING THEM, AND METHODS OF THEIR USE
PH12019501130A1 (en) Viral delivery of neoantigens
EP3821011A4 (en) TRANSPOSOME-ENABLED DNA/RNA SEQUENCING (TED RNA-SEQUENCING)
MX2022006652A (en) Modified capsid proteins for enhanced delivery of parvovirus vectors.
HK1202434A1 (en) Virus vectors for highly efficient transgene delivery
WO2013110818A3 (en) Immunogens for hiv vaccination
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
WO2013096866A3 (en) Processes using vlps with capsids resistant to hydrolases
MX2014004214A (en) Recombinant self-replicating polycistronic rna molecules.
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
IL233773B (en) Methods for detecting a target nucleic acid sequence from a dna or a mixture of nucleic acids and a kit for performing such methods
WO2013170170A3 (en) Compositions and methods for gene therapy
EP3638317A4 (en) TARGETED INSERTIONS OF NON-VIRAL DNA
WO2012142434A3 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EA201692359A1 (en) COMPOSITION BASED ON NEW PRRSV STRAIN OR HIS PROTEINS, PRODUCT, THEIR USE, PRRSV VIRUS, ISOLATED NK AND A RECOMBINANT VECTOR OF EXPRESSION FOR OBTAINING THIS VIRUS
EA202092990A3 (en) NUCLEIC ACID MOLECULE CODING THE HEPATITIS B VIRUS CORE PROTEIN AND VACCINE CONTAINING THE INDICATED MOLECULE
WO2015052543A3 (en) Malaria vaccination
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
EP3997205A4 (en) Rna sequencing methods
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2009124137A3 (en) Method of suppressing gene transcription through histone lysine methylation
EP3963106A4 (en) Methods of sequencing nucleic acid molecules
MX390966B (en) Dengue vaccines
WO2012116253A3 (en) Recombinant mumps virus vaccine
WO2015123592A3 (en) Recombinant rna particles and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11876707

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11876707

Country of ref document: EP

Kind code of ref document: A2